CAR T-Cell Therapy in Multiple Myeloma : Episode 1
Navigating the Myeloma Journey: Insights from Diagnosis to First-Line Treatment in Standard-Risk Patient
Panelists discuss how the patient’s journey with multiple myeloma begins with an initial diagnosis followed by first-line treatments and how this informs the decision to consider chimeric antigen receptor T-cell therapy as a subsequent option in their treatment path.
Video Player is loading.
Now Viewing
EP: 1.Navigating the Myeloma Journey: Insights from Diagnosis to First-Line Treatment in Standard-Risk Patient
EP: 2.Exploring CAR-T Therapy: Discussing Its Introduction and Shared Decision-Making in Myeloma Treatment
EP: 3.CAR-T Therapy in Standard-Risk Multiple Myeloma: Rationale and Patient Preparation
EP: 4.CAR-T Therapy Journey: From Cell Collection to Managing Challenges
EP: 5.Preparing for CAR-T Therapy: Key Considerations and Timing in Multiple Myeloma Treatment
EP: 6.Managing CAR-T Therapy: Side Effect Monitoring and Collaborative Patient Care
EP: 7.Navigating Recovery: CAR-T Cell Therapy Experience
EP: 8.Navigating the Long-Term Landscape: CAR-T Therapy Patient Monitoring and Care
EP: 9.Navigating My Myeloma Journey: Insights and Advice on CAR-T Therapy
EP: 10.The Future of CAR-T: Advancing Myeloma Treatment Strategies
Video content above is prompted by the following:
Can you share your journey with multiple myeloma, starting with your initial diagnosis and first-line treatment?
Recent Videos
The Role of Molecular Testing in Ovarian Cancer Care
Managing Recurrent Ovarian Cancer: Tailoring Approaches Based on Platinum Sensitivity
Immunotherapy Dosing Strategies: Optimizing Efficacy and Managing Toxicity in Melanoma
Managing Expectations: Adverse Events With Melanoma Immunotherapy
NALIRIFOX In Practice: Treatment Strategies for Patients With mPDAC
Evaluating the Impact Of UGT1A1*28 Status On Tolerability Of NALIRIFOX In mPDAC
NAPOLI-3 in Real World Practice: Expert Insights on Data From ASCO GI 2025
Managing AEs Associated With the FOLFIRINOX and NALIRIFOX Regimens in Pancreatic Cancer
Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue
CRS Recognition and Intervention: Timing and Clinical Features
Related Content
